Summary | |
---|---|
Symbol | PLAUR |
Name | plasminogen activator, urokinase receptor |
Aliases | URKR; UPAR; CD87; urokinase-type plasminogen activator (uPA) receptor; urokinase plasminogen activator surfa ...... |
Chromosomal Location | 19q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell membrane Cell projection, invadopodium membrane Note=Colocalized with FAP (seprase) preferentially at the cell surface of invadopodia membrane in a cytoskeleton-, integrin- and vitronectin-dependent manner. ; SUBCELLULAR LOCATION: Isoform 1: Cell membrane Lipid-anchor, GPI-anchor ; SUBCELLULAR LOCATION: Isoform 2: Secreted |
Domain |
PF00021 u-PAR/Ly-6 domain |
Function |
Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form. |
Biological Process |
GO:0001836 release of cytochrome c from mitochondria GO:0006497 protein lipidation GO:0006505 GPI anchor metabolic process GO:0006506 GPI anchor biosynthetic process GO:0006643 membrane lipid metabolic process GO:0006644 phospholipid metabolic process GO:0006650 glycerophospholipid metabolic process GO:0006661 phosphatidylinositol biosynthetic process GO:0006664 glycolipid metabolic process GO:0007173 epidermal growth factor receptor signaling pathway GO:0007596 blood coagulation GO:0007599 hemostasis GO:0008637 apoptotic mitochondrial changes GO:0008654 phospholipid biosynthetic process GO:0009247 glycolipid biosynthetic process GO:0010466 negative regulation of peptidase activity GO:0010821 regulation of mitochondrion organization GO:0010822 positive regulation of mitochondrion organization GO:0010951 negative regulation of endopeptidase activity GO:0016255 attachment of GPI anchor to protein GO:0030193 regulation of blood coagulation GO:0030195 negative regulation of blood coagulation GO:0032102 negative regulation of response to external stimulus GO:0038127 ERBB signaling pathway GO:0038195 urokinase plasminogen activator signaling pathway GO:0042058 regulation of epidermal growth factor receptor signaling pathway GO:0042157 lipoprotein metabolic process GO:0042158 lipoprotein biosynthetic process GO:0042730 fibrinolysis GO:0043154 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043388 positive regulation of DNA binding GO:0045017 glycerolipid biosynthetic process GO:0045742 positive regulation of epidermal growth factor receptor signaling pathway GO:0045861 negative regulation of proteolysis GO:0046467 membrane lipid biosynthetic process GO:0046474 glycerophospholipid biosynthetic process GO:0046486 glycerolipid metabolic process GO:0046488 phosphatidylinositol metabolic process GO:0050817 coagulation GO:0050818 regulation of coagulation GO:0050819 negative regulation of coagulation GO:0050878 regulation of body fluid levels GO:0051098 regulation of binding GO:0051099 positive regulation of binding GO:0051101 regulation of DNA binding GO:0051346 negative regulation of hydrolase activity GO:0052547 regulation of peptidase activity GO:0052548 regulation of endopeptidase activity GO:0061041 regulation of wound healing GO:0061045 negative regulation of wound healing GO:0090199 regulation of release of cytochrome c from mitochondria GO:0090200 positive regulation of release of cytochrome c from mitochondria GO:0097193 intrinsic apoptotic signaling pathway GO:1900046 regulation of hemostasis GO:1900047 negative regulation of hemostasis GO:1901184 regulation of ERBB signaling pathway GO:1901186 positive regulation of ERBB signaling pathway GO:1902532 negative regulation of intracellular signal transduction GO:1903034 regulation of response to wounding GO:1903035 negative regulation of response to wounding GO:1903509 liposaccharide metabolic process GO:2000116 regulation of cysteine-type endopeptidase activity GO:2000117 negative regulation of cysteine-type endopeptidase activity GO:2001233 regulation of apoptotic signaling pathway GO:2001234 negative regulation of apoptotic signaling pathway GO:2001235 positive regulation of apoptotic signaling pathway GO:2001242 regulation of intrinsic apoptotic signaling pathway GO:2001243 negative regulation of intrinsic apoptotic signaling pathway GO:2001267 regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:2001268 negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway |
Molecular Function |
GO:0030377 urokinase plasminogen activator receptor activity |
Cellular Component |
GO:0005788 endoplasmic reticulum lumen GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0019898 extrinsic component of membrane GO:0030055 cell-substrate junction GO:0031225 anchored component of membrane GO:0031253 cell projection membrane GO:0071437 invadopodium GO:0071438 invadopodium membrane |
KEGG |
hsa04610 Complement and coagulation cascades |
Reactome |
R-HSA-162791: Attachment of GPI anchor to uPAR R-HSA-75205: Dissolution of Fibrin Clot R-HSA-109582: Hemostasis R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-392499: Metabolism of proteins R-HSA-6798695: Neutrophil degranulation R-HSA-163125: Post-translational modification R-HSA-597592: Post-translational protein modification |
Summary | |
---|---|
Symbol | PLAUR |
Name | plasminogen activator, urokinase receptor |
Aliases | URKR; UPAR; CD87; urokinase-type plasminogen activator (uPA) receptor; urokinase plasminogen activator surfa ...... |
Chromosomal Location | 19q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between PLAUR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between PLAUR and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | PLAUR |
Name | plasminogen activator, urokinase receptor |
Aliases | URKR; UPAR; CD87; urokinase-type plasminogen activator (uPA) receptor; urokinase plasminogen activator surfa ...... |
Chromosomal Location | 19q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of PLAUR in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | PLAUR |
Name | plasminogen activator, urokinase receptor |
Aliases | URKR; UPAR; CD87; urokinase-type plasminogen activator (uPA) receptor; urokinase plasminogen activator surfa ...... |
Chromosomal Location | 19q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of PLAUR in various data sets.
|
Points in the above scatter plot represent the mutation difference of PLAUR in various data sets.
|
Summary | |
---|---|
Symbol | PLAUR |
Name | plasminogen activator, urokinase receptor |
Aliases | URKR; UPAR; CD87; urokinase-type plasminogen activator (uPA) receptor; urokinase plasminogen activator surfa ...... |
Chromosomal Location | 19q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PLAUR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | PLAUR |
Name | plasminogen activator, urokinase receptor |
Aliases | URKR; UPAR; CD87; urokinase-type plasminogen activator (uPA) receptor; urokinase plasminogen activator surfa ...... |
Chromosomal Location | 19q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PLAUR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PLAUR. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | PLAUR |
Name | plasminogen activator, urokinase receptor |
Aliases | URKR; UPAR; CD87; urokinase-type plasminogen activator (uPA) receptor; urokinase plasminogen activator surfa ...... |
Chromosomal Location | 19q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PLAUR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | PLAUR |
Name | plasminogen activator, urokinase receptor |
Aliases | URKR; UPAR; CD87; urokinase-type plasminogen activator (uPA) receptor; urokinase plasminogen activator surfa ...... |
Chromosomal Location | 19q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of PLAUR expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | PLAUR |
Name | plasminogen activator, urokinase receptor |
Aliases | URKR; UPAR; CD87; urokinase-type plasminogen activator (uPA) receptor; urokinase plasminogen activator surfa ...... |
Chromosomal Location | 19q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between PLAUR and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | PLAUR |
Name | plasminogen activator, urokinase receptor |
Aliases | URKR; UPAR; CD87; urokinase-type plasminogen activator (uPA) receptor; urokinase plasminogen activator surfa ...... |
Chromosomal Location | 19q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting PLAUR collected from DrugBank database. |
Details on drugs targeting PLAUR.
|